Search company, investor...
Voyage Medical company logo

Voyage Medical

voyagemedical.com

Founded Year

2006

Stage

Debt | Dead

Total Raised

$44.41M

Last Raised

$370K

About Voyage Medical

Voyage Medical is developing a medical imaging and therapeutic technology that will transform therapy in percutaneous intracardiac procedures. The Direct Endocardial Visualization Ablation Catheter - IRIS System provides physicians a real-time high-resolution color view of treatment areas, such as in the ablation of Atrial Fibrillation (AF). The IRIS Cardiac Ablation Catheter enables Electrophysiologists to visually guide energy delivery to targeted endocardial anatomy during percutaneous AF ablation procedures, ensuring optimal lesion formation and no gaps.

Headquarters Location

610 Galveston Drive

Redwood City, California, 94063,

United States

650-503-7500

Missing: Voyage Medical's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Voyage Medical's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Voyage Medical Patents

Voyage Medical has filed 13 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/13/2011

4/16/2013

Medical ultrasonography, Medical imaging, Medical equipment, Magnetic resonance imaging, Iodoarenes

Grant

Application Date

9/13/2011

Grant Date

4/16/2013

Title

Related Topics

Medical ultrasonography, Medical imaging, Medical equipment, Magnetic resonance imaging, Iodoarenes

Status

Grant

Voyage Medical Frequently Asked Questions (FAQ)

  • When was Voyage Medical founded?

    Voyage Medical was founded in 2006.

  • Where is Voyage Medical's headquarters?

    Voyage Medical's headquarters is located at 610 Galveston Drive, Redwood City.

  • What is Voyage Medical's latest funding round?

    Voyage Medical's latest funding round is Debt.

  • How much did Voyage Medical raise?

    Voyage Medical raised a total of $44.41M.

  • Who are the investors of Voyage Medical?

    Investors of Voyage Medical include RWI Ventures, Three Arch Partners and Kleiner Perkins Caufield & Byers.

  • Who are Voyage Medical's competitors?

    Competitors of Voyage Medical include Reva Medical, TriVascular Technologies, Veryan Medical, Flexuspine, CardioMind and 12 more.

Compare Voyage Medical to Competitors

Endologix Logo
Endologix

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.

X
XTENT

Based in Menlo Park, California, Xtent Inc. is a privately held developer of next generation drugeluting stent (DES) systems designed for the treatment of real-world patients, including those with complex, multi-lesion or multi-vessel coronary and peripheral vascular disease. Although the drugeluting stent (DES) market is today dominated by large companies, the interventional cardiology field has seen many technological breakthroughs that have changed market leadership.

E
Embolic Protection

Devices for the prevention of embolic complications including stroke and heart attack during interventional vascular procedures. Acquired by Boston Scientific in 2001.

Veryan Medical Logo
Veryan Medical

Veryan is developing innovative solutions to improve the performance of vascular stents using the principles of biomimicry. Veryan's BioMimics 3D stent technology involves adapting traditional straight stent designs to a patented three-dimensional helical shape, which more closely mimics the natural geometry of the human vascular system. BioMimics 3D technology has been proven to enhance clinical performance by improving flow conditions in, and the biomechanical performance of, stented vessels. The advanced, biomimetic design of the BioMimics 3D stent is intended to provide improved flow conditions and more flexibility, kink and fracture resistance than other nitinol stents. Veryan's Research & Development facility is located in Galway, Ireland.

K
Kspine

Kspine is developing implantable medical devices for the treatment of spine disorders.

S
Satiety

Satiety, Inc. is a medical device company focused on the development of less invasive devices for the treatment of obesity. Obesity is a global health problem, affecting 70 million people in the U.S. and 300 million worldwide, and growth of which is causing increases in obesity-related diseases such as diabetes, high blood pressure and cardiovascular disease. Obesity surgery has been shown to be the only long-term effective means of weight loss for morbidly obese patients. Satiety's first product, the TOGA System, enables physicians to perform a procedure similar to traditional restrictive obesity surgeries, but without surgical incisions. In this procedure, the TOGA System devices are inserted transorally (through the mouth) and are used to reduce the capacity of the stomach to give patients a feeling of fullness after a small meal. The procedure is intended to be safer and easier for patients to tolerate than conventional obesity surgery. Safety and effectiveness of the TOGA System are currently being evaluated in a multi-center U.S. Study and the system is not available for sale in the United States.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.